Forest Laboratories, Inc.
(NYSE: FRX) and PAION AG (Aachen, Germany — Frankfurt Reserve Unpleasantness,
Prime Standard: PA8) today announced topline results of the DIAS-2
(Desmoteplase In Grave Ischemic Stroke) analyse with the compound
Desmoteplase. The Include III lucubrate was designed to inquire into the
progress of clinical pay-off in patients with excruciating ischemic stroke
treated with Desmoteplase within 3 to 9 hours after dawn of dash
symptoms as compared to placebo. The primary efficacy endpoint (difference
between active treatment and placebo in piece of composite responders
as defined below) was not met. The blinded, randomized, placebo-controlled,
dose-ranging whirl was jointly conducted by PAION and Forest Laboratories,
Inc., and enrolled a all-out of 186 patients in Europe, USA, Canada,
Australia, Hong Kong and Singapore. Forest Laboratories, Inc. is the
partner of PAION suitable Desmoteplase concerning North America and H. Lundbeck A/S is
PAION’s partner in the direction of the rest of the world.
In this swatting, patients received either placebo (N=63), 90 mcg/kg
(N=57), or 125 mcg/kg (N=66) of Desmoteplase as an intravenous bolus within
3-9 hours after the onset of hint. Patients were unwed for treatment
only in cause of a distinct penumbra of at least 20% (insufficiently
perfused but still salvageable tissue area around the cardinal location of
stroke), which was confirmed by magnetic resonance imaging (MRI) or
perfusion computed tomography (pCT).
The zenith efficacy endpoint in the study was clinical advance at
Date 90 defined in the direction of each patient as achievement of all three of the
following criteria; (1): Improvement of greater than or equal to 8 points
from baseline on the National Institutes of Health Stroke Ascend (NIHSS) or
NIHSS score less than or fellow to 1, (2): Modified Rankin Scale (MRS) total
of 0-2, and (3): Barthel Index (BI) account of 75-100. At worst patients who
simultaneously met the criteria along all three scales were considered
responders. Patients defined as responders by such criteria are in general
able to function independently, having no or few deficits.
Improvement of clinical outcome was found with 47.4% of patients
treated with 90 mcg/kg Desmoteplase and 36.4% of patients treated with 125
mcg/kg Desmoteplase, compared to 46.0% in the placebo sort with neither
amount of Desmoteplase statistically significantly different compared to
placebo.
The rate of symptomatic intracranial bleeding within 72 hours after
study drug government was 0% in the placebo band, 3.5% in the 90
mcg/kg dose collect and 4.5% in the 125 mcg/kg group. There were four patient
deaths reported in the placebo bracket, three reported in the 90 mcg/kg measure
set and 14 reported in the 125 mcg/kg administer group within the 90 day
follow-up period. Ten of the 14 deaths in the 125 mcg/kg portion group were
considered by the investigators as not related to the drug, 9 of which
occurred 14 or more days after aneurysm and were from non-neurological
causes.
These data are surprising and are not harmonious with previously
observed patterns in the DIAS/DEDAS trials and larger size,
placebo-controlled alert attack trials. The absence of consistency with
past findings is not easy to unravel, but in-depth analyses are planned
to better tolerate the data.
Forest will review the complete analyse database over the coming weeks to
settle the happy next steps and its place regarding U.S.
development of desmoteplase.
The headline results of the DIAS-2 work will be presented on 1 June
2007 at 10:45 a.m. BST within the “Large Clinical Trials II” session at the
XVI European Stroke Convention in Glasgow, Scotland, U.K.
PAION will landlady a talk phone call on 1 June 2007 to consult on the DIAS-2
headline results starting at 1:00 p.m. BST (02:00 p.m. CEST, 08:00 a.m.
EDT).
In wing as well as, a webcast of the conference call (listen-on the contrary mode) will
be accessible through a link provided on PAION’s corporate website at
http://www.paion.de.
All round Desmoteplase
Desmoteplase, the most fibrin-definite plasminogen activator known
today, is a genetically engineered clot-dissolving protein inaugurate in the
saliva of the vampire bat Desmodus rotundus. It has received express-chase
designation from the U.S. Foodstuffs and Drug Administration for the indication
of severe ischemic occurrence.
About Move
According to a recent magazine by the American Aneurysm Association
(ASA), caress at the present time is the favour leading cause of demise worldwide and is a
leading cause of serious, hunger-assumptions agree disability. In the U.S. alone, 700,000
people suffer a stroke each year, and approximately 20% die within four
weeks. For the U.S., the American Guts Association (AHA) expects the
financial burden of stroke due to in-hospital costs, long-while care
programs and productivity losses to be 63 billion dollars in 2007 alone.
About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical
company dedicated to identifying, developing and delivering products that
make a positive difference in peoples’ lives. Forest Laboratories’ growing
fallout put includes Lexapro(R) (escitalopram oxalate), an SSRI indicated
for adults in regard to the initial and maintenance treatment of major depressive
disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an
N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer’s disease; Benicar(R)
(olmesartan medoxomil), an angiotensin receptor blocker, and Benicar
HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor
blocker and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated in
combination with psychosocial support for the maintenance of abstinence
from alcohol in patients with juice dependence who are abstinent at
treatment establishment.
Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral
is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
Except through despite the authentic information contained herein, this release
contains “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements comprise a number
of risks and uncertainties, including the predicament of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
catapult of new products, and the jeopardize factors listed from unceasingly a once to time in
the Forest Laboratories’ SEC reports, including the Company’s Annual Report
on Form 10-K concerning the pecuniary year ended March 31, 2007.
Forest Laboratories, Inc.
http://www.frx.com
View drug information on Benicar; Campral; Lexapro.